Humanwell Healthcare (Group) Co. Ltd. has identified transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have divulged trideuteromethyl-substituted pyrazino pyrazino quinolinone derivatives acting as deuterated GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.
Biogen Inc. and C4 Therapeutics Inc. have synthesized proteolysis targeting chimeric (PROTAC) compounds comprising cereblon (CRBN) ligands covalently linked to an IL-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a GTPase KRAS (G12D mutant) targeting moiety reported to be useful for the treatment of cancer.
Accutar Biotechnology Inc. has received FDA clearance of its IND application for AC-0676 for the treatment of patients with relapsed/refractory B-cell malignancies.
Lung and pancreatic cancer cells usually become chemotherapy resistant; the alternative to target nonapoptotic pathways was hypothesized as an approach for treating these cancers. Researchers from Sun Yat-sen University and their collaborators focused on the activation of pyroptosis as a therapeutic alternative to treat these resistant tumor types.
Egret Therapeutics, a portfolio company of Turret Capital Management LP, has announced FDA clearance of its IND application for EGT-101 for the treatment of delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage.
Inmagene Biopharmaceuticals Co. Ltd. has obtained IND approval from the FDA for IMG-008, the company's novel long-acting antagonistic humanized monoclonal antibody that specifically targets human IL-36 receptor (IL-36R) to treat auto-inflammatory diseases.
Researchers from South China University of Technology and Chengde Medical University presented the discovery and preclinical evaluation of novel xanthine oxidoreductase (XOR) inhibitors as potential uric acid-lowering agents.
RSS
